Skip to main content
profile image
Selected Works of Meejin Ahn
Article
Analysis of GP73 in patients with HCC as a function of anti-cancer treatment
Cancer Biomarkers (2011)
  • Hie-Won Hann
  • Mengjun Wang
  • Julie Hafner
  • Ronald E Long
  • Su Hee Kim
  • Meejin Ahn, Philadelphia College of Osteopathic Medicine
  • Susan Park
  • Mary Ann Comunale
  • Timothy M Block
  • Anand Mehta
Link Find in your library
Abstract
In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.
Disciplines
Publication Date
June, 2011
DOI
https://doi.org/10.3233/cbm-2010-0190
Citation Information
Hie-Won Hann, Mengjun Wang, Julie Hafner, Ronald E Long, et al.. "Analysis of GP73 in patients with HCC as a function of anti-cancer treatment" Cancer Biomarkers Vol. 7 Iss. 6 (2011) p. 269 - 273
Available at: http://works.bepress.com/meejin-ahn/3/